Gut Microbes May Explain Why Obesity and Type 2 Diabetes Become Harder to Reverse
核心洞察
A new review in npj Biofilms and Microbiomes (搜索) maps how gut microbial messengers disrupt appetite control, insulin sensitivity, and pancreatic function via the microbiota-gut-brain axis.
Gut dysbiosis triggers systemic inflammation, impairs GLP-1 (搜索) and PYY (搜索) secretion, and drives hypothalamic insulin resistance, reinforcing a vicious cycle in obesity (搜索) and type 2 diabetes (搜索).
Emerging therapeutic strategies include prebiotics, probiotics, receptor-targeted approaches, and neuromodulation, though clinical translation requires patient stratification and personalized approaches.
A comprehensive review published as an Article in Press in the journal npj Biofilms and Microbiomes (搜索) systematically maps how gut microbial messengers contribute to the pathophysiology of obesity (搜索) and type 2 diabetes (搜索) through the microbiota-gut-brain axis, offering a framework for more targeted therapeutic interventions in metabolic disease.
The microbiota-gut-brain axis is a bidirectional communication network linking the gut microbiota and the central nervous system through neural, endocrine, immune, and metabolic pathways. The review authors describe how metabolites and microbial particles—including short-chain fatty acids (搜索) (SCFAs), microbiota-modified bile acids, neuroactive substances, and extracellular vesicles—can directly or remotely modulate the brain's metabolic pathways to establish host metabolic homeostasis.
Hypothalamic Disruption and Energy Balance
The hypothalamus plays a central role in maintaining the balance between energy consumption and expenditure. SCFAs such as acetate, produced by beneficial microbial populations, support hypothalamic signaling pathways that promote satiety and increase energy expenditure. In obesity (搜索), this mechanism is significantly attenuated. Conversely, gut microbiota dysbiosis triggered by a high-fat diet increases gut-derived lipopolysaccharide translocation and reduces circulating SCFAs, leading to neuroinflammation and impairment of hypothalamic insulin sensitivity—two key mechanistic features linked to obesity.
Adipose Tissue as a Signaling Hub
Adipose tissue acts as an active signaling hub, secreting adipokines and cytokines while receiving signals from the gut microbiota. Gut-derived lipopolysaccharide translocation triggers proinflammatory responses in adipose tissue, leading to local insulin resistance. This is further facilitated by systemic depletion of beneficial SCFAs and resulting attenuation of systemic anti-inflammatory responses. In this proinflammatory environment, adipose tissue releases large amounts of inflammatory cytokines and free fatty acids into the blood, which subsequently enter the brain by altering blood-brain barrier permeability and disrupting hypothalamic energy-balance signaling.
The Incretin Axis and Gut-Brain Satiety Signals
The synthesis and release of core intestinal hormones, including GLP-1 (搜索) and PYY (搜索), which regulate satiety, insulin secretion, and energy homeostasis, are precisely controlled by gut microbial metabolites. In obesity (搜索), gut microbiota dysbiosis reduces the abundance of SCFA-producing beneficial bacteria, disrupting intestinal hormone secretion. Furthermore, the circulating lipotoxic environment induced by microbial dysbiosis increases free fatty acid levels, which impair GLP-1 production by inducing endoplasmic reticulum stress in intestinal hormone-producing cells. This communication breakdown, together with adipose tissue-mediated inflammatory responses and local insulin resistance, may trigger the development and progression of obesity.
Microbial Messengers and Type 2 Diabetes (搜索) Pathogenesis
The pathogenesis of type 2 diabetes (搜索) is strongly associated with impaired insulin signaling, and dysregulated microbial metabolites significantly contribute to this impairment by triggering hypothalamic inflammation. Microbial dysbiosis-mediated disruption of intestinal barrier integrity leads to translocation of bacterial lipopolysaccharides to the liver via the portal circulation. These lipopolysaccharides activate resident liver macrophages and trigger the release of inflammatory cytokines, which block insulin signal transduction in liver cells. In skeletal muscle, systemic low-grade inflammation driven by gut leakage and adipose tissue inflammation further disrupts insulin signaling. Ultimately, impaired central and peripheral insulin signaling reinforce each other through a positive feedback loop initiated by dysregulation of microbial metabolites.
Pancreatic Beta Cell Exhaustion
Increased acetate production due to high-fat diet intake activates the parasympathetic nervous system, leading to increased secretion of the hunger hormone ghrelin and glucose-stimulated insulin secretion. This premature and excessive secretory demand exhausts pancreatic beta cells, leading to impaired insulin secretion and reduced insulin sensitivity—two major hallmarks of type 2 diabetes (搜索). Persistently high blood glucose levels also downregulate GLP-1 (搜索) receptor expression on pancreatic beta cells and hypothalamic neurons, weakening the gut-brain insulinotropic pathway.
Immune Dysregulation and a Closed-Loop Cycle
Dysbiosis of the gut microbiota and related disruptions in microbial metabolites impair intestinal barrier integrity, compromise the immune defense line, and induce systemic inflammation. This causes peripheral insulin resistance, pancreatic beta cell damage, and neuroinflammation in the hypothalamus. The resulting closed-loop cycle further impairs hypothalamic insulin signaling, triggers central insulin resistance, and alters autonomic output, worsening regulation of peripheral glucose metabolism.
Therapeutic Frontiers and Clinical Translation Challenges
The review highlights emerging strategies targeting the microbiota-gut-brain axis, including ecological remodeling with prebiotics and probiotics to increase beneficial microbial messengers, receptor-targeted approaches that mimic protective metabolites or block harmful inflammatory signals, and neuromodulation strategies aimed at restoring gut-brain communication.
However, the authors emphasize that clinical translation remains challenging. Responses to microbiota-gut-brain axis-targeted interventions are likely to depend on host genetics, diet, baseline microbiome composition, metabolic status, and disease stage, underscoring the importance of patient stratification and personalized approaches for future research.
Recent evidence suggests that altered composition and diversity of the gut microbiota can precede and may contribute to the development of metabolic diseases like obesity (搜索) and type 2 diabetes (搜索) long before their clinical diagnosis. The review supports the microbiota-gut-brain axis theory as a novel perspective for understanding these complex metabolic disorders, and targeting this axis with novel interventions could represent a promising, yet still developing, strategy to address the global public health challenges associated with these diseases.